Free Trial

Xilio Therapeutics (XLO) Insider Trading & Ownership

Xilio Therapeutics logo
$1.32
+0.05 (+3.94%)
(As of 11/1/2024 ET)

Xilio Therapeutics (NASDAQ:XLO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
5.20%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$368,790.00
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$1,831.54
Get XLO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

XLO Insider Buying and Selling by Quarter

Xilio Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/2/2024Gilead Sciences, Inc.Major ShareholderBuy485,250$0.76$368,790.00  
2/8/2024Venture Fund Xi L.P. AtlasMajor ShareholderSell733$0.64$469.12  
1/11/2024Venture Fund Xi L.P. AtlasMajor ShareholderSell1,566$0.87$1,362.42  
(Data available from 1/1/2013 forward)

XLO Insider Trading Activity - Frequently Asked Questions

The list of insiders at Xilio Therapeutics includes Bain Capital Life Sciences Inv, Gilead Sciences, Inc., and Venture Fund Xi L.P. Atlas. Learn more on insiders at XLO.

5.20% of Xilio Therapeutics stock is owned by insiders. Learn more on XLO's insider holdings.

The following insider purchased XLO shares in the last 24 months: Gilead Sciences, Inc. ($368,790.00).

Insiders have purchased a total of 485,250 XLO shares in the last 24 months for a total of $368,790.00 bought.

The following insider sold XLO shares in the last 24 months: Venture Fund Xi L.P. Atlas ($1,831.54).

Insiders have sold a total of 2,299 Xilio Therapeutics shares in the last 24 months for a total of $1,831.54 sold.

Xilio Therapeutics Key Executives

  • Dr. Rene Russo BCPS (Age 49)
    Pharm.D., President, CEO & Director
    Compensation: $875.13k
  • Mr. Christopher Frankenfield (Age 42)
    Chief Operating Officer
    Compensation: $704.85k
  • Dr. Katarina Luptakova M.D. (Age 48)
    Chief Medical Officer
    Compensation: $591.92k
  • Mr. Kevin M. Brennan (Age 54)
    Senior VP of Finance & Accounting
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Dr. Scott Coleman Ph.D.
    Chief Development Officer


This page (NASDAQ:XLO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners